Pharmaceuticals, Biotechnology and Life Sciences
German drugmaker Stada has confirmed certain rumours about receiving takeover offers from a private equity firm, Cinven Partners and one other unnamed bidder.
Evgen Pharma has signed a services agreement with APTrans for developing its anti-stress drug SFX-01, currently in phase II clinical testing. APTrans is a Cheshire-based consortium of drug development companies.
Premaitha has signed four-year Master Procurement Agreement (the “MPA”) with a European diagnostics services group to install the IONA test in at least two of the Groups’s laboratories.
“The new funds we are raising will support the ongoing progress of these important assets as well as the rest of our pipeline and we remain very positive about Redx’s prospects.”
Cancer Research UK (CR UK), the world’s largest not-for-profit cancer research organization, has today announced that six leading U.S. scientists are among the winners of a global competition to help overcome the biggest challenges facing cancer research.
Immunomedics Inc has concluded a $2 billion worth deal with Seattle based developer of antibody-drug conjugates (ACDs) for treating late stage cancer based on which Seattle Genetics will develop, fund, manufacture and commercialize IMMU-132, Immunomedics’ proprietary solid tumor therapy candidate.
Neurocrine Biosciences has made a deal with BIAL to develop and sell Ongentys opicapone inhibitor for Parkinson’s patients, in North America.
Amgen co-founder Dr. Joseph Rubinfeld, who was an independet director of Amarantus BioScience Holdings has died.
Canadian commercial dermatology company Crescita Therapeutics has named its Corporate Controller Ms. Muneerah Kanji as Interim Chief Financial Officer.
Aytu BioScience, a drugmaker focused on urology products, has increased gross product sales by 47% from the quarter ended September 30, 2016 to the quarter ended December 31, 2016, from $925,000 to $1,358,000, getting its first ever $1M-plus quarter sales.